Emblaveo® (Aztreonam-Avibactam) Aztreonam-avibactam powder for intravenous infusion by AbbVie (US); Pfizer (EU). Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Aztreonam 500 mg + Avibactam 167 mg |
|---|---|
| Manufacturer | AbbVie / Pfizer |
| Country | USA / Europe |
| Pack size | 1 vial |
| Storage | Store as stated on the carton and prescribing information |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Emblaveo® (Aztreonam-Avibactam) Powder for Intravenous Infusion: A Sourcing Guide for Hospitals and Pharmacies
Emblaveo® is a fixed combination of aztreonam (a monobactam antibacterial) and avibactam (a β-lactamase inhibitor) for intravenous use. Whether and how to use it, including patient selection, dose and microbiology review, rests entirely with the treating physician and the hospital antimicrobial stewardship team. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Emblaveo® (aztreonam-avibactam) powder for intravenous infusion to hospitals and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the Anti-Biotic category. Supply is in bulk/wholesale quantities only.
Emblaveo contains aztreonam and avibactam, supplied as a powder for reconstitution and intravenous infusion. The European presentation is listed as 500 mg aztreonam with 167 mg avibactam per vial; please confirm the strength and pack against the carton before ordering. It is not an immunosuppressant or an emapalumab product, and an earlier version of this page described it incorrectly.
How it works, according to the label: The US prescribing information (AbbVie) describes Emblaveo as the combination of a monobactam and a β-lactamase inhibitor, with in vitro activity against Enterobacterales producing certain β-lactamases, including metallo-β-lactamases such as NDM. In vitro activity does not necessarily correlate with clinical efficacy.
Carbapenem-resistant Enterobacterales (CRE) are gram-negative bacteria that no longer respond to carbapenems, antibiotics that hospitals often keep for serious infections. The World Health Organization lists carbapenem-resistant Enterobacterales among its critical-priority bacterial pathogens, and hospital infection-control and antimicrobial-stewardship teams track them closely.
Metallo-beta-lactamases such as NDM are enzymes that break down carbapenems and are not blocked by several older beta-lactamase inhibitors. Aztreonam is a monobactam that is stable against metallo-beta-lactamases, and avibactam inhibits other beta-lactamases that can degrade aztreonam; the label describes the combination on that basis. Whether any antibacterial is appropriate for a given infection is a matter for the treating physician, the microbiology results and hospital policy.
The current US prescribing information for Emblaveo lists the following. Indications in other countries, including India, are defined by the local regulator and the pack insert.
Published studies include the REVISIT phase 3 trial of aztreonam-avibactam in serious infections caused by gram-negative bacteria (Lancet Infect Dis, 2025) and the ASSEMBLE study in patients with metallo-β-lactamase-producing infections. Results and conclusions are those of the trial authors and the prescribing information; A.K. Pharma does not interpret them.
| Strength | Dosage form | Pack (confirm against the carton) |
|---|---|---|
| Aztreonam 500 mg + avibactam 167 mg (EU presentation) | Powder for concentrate for solution for infusion | Vial (confirm against the carton) |
Please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
When a hospital purchase department or pharmacy evaluates Emblaveo, the usual first checks are the same as for any specialty medicine: the supplier’s wholesale drug licence and GST registration, a proper tax invoice for every consignment, and written confirmation that the stock comes from an authorised channel. A.K. Pharma supplies Emblaveo as a licensed distributor and shares the batch number, manufacturing and expiry dates and pack details on request, so that your receiving team can match the carton against the invoice before the stock is accepted.
On delivery, buyers commonly check that the carton is sealed and undamaged, that the batch number and expiry date on the carton match the invoice, and that the product is stored as directed on the pack. Any discrepancy should be reported to the supplier at once, before the product is issued for use.
Orders are supplied in bulk and wholesale quantities only, to hospitals, clinics, doctors and pharmacies. Availability, pack presentation and lead time can change with manufacturer supply, so please contact A.K. Pharma for current stock before you raise a purchase order. A.K. Pharma does not provide clinical guidance; questions about whether Emblaveo is suitable for a particular patient belong with the treating physician and the product’s approved prescribing information.
Hospital pharmacies, infectious disease and critical care units, and procurement departments in India that need to source Emblaveo in bulk quantities from a licensed distributor.
The US label lists hypersensitivity reactions, serious skin disorders, hepatic adverse reactions and Clostridioides difficile-associated diarrhoea among its warnings. It is contraindicated in patients with known hypersensitivity to aztreonam or avibactam. The most common adverse reactions (over 5%) listed were hepatic adverse reactions, anaemia, diarrhoea, hypokalaemia and pyrexia. Refer to the full label and consult the treating physician.
All use should follow the approved prescribing information and the instructions of the treating physician.
Store as directed on the carton and in the prescribing information. Reconstituted and diluted solutions have limited stability; follow the label.
Emblaveo is marketed by AbbVie in the United States and by Pfizer in Europe; the Indian marketer should be confirmed against the carton. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Emblaveo through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Emblaveo available in India?
A.K. Pharma supplies Emblaveo® (aztreonam-avibactam) powder for intravenous infusion to hospitals and pharmacies in India. Contact us for current availability.
What does Emblaveo contain?
Emblaveo contains aztreonam-avibactam, marketed by AbbVie (US); Pfizer (EU). The details of use are those on its label.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
Is Emblaveo the same as Emapalumab?
No. Emblaveo is aztreonam-avibactam, an antibacterial. Emapalumab is a different medicine and an earlier version of this page was incorrect.
Which strength does A.K. Pharma supply?
Contact us for the current presentation, pack and batch availability.
What is Emblaveo made of?
It is a fixed combination of aztreonam and avibactam, as described in the label.
Why does stewardship matter for this product?
The label says it should be used only for infections proven or strongly suspected to be caused by susceptible bacteria, to reduce the development of drug-resistant bacteria. Those decisions rest with the treating physician and hospital policy.
Does the US label apply in India?
No. Indications in other countries are set by the local regulator, so please read the pack insert supplied with the stock.
What warnings does the US label list?
The label lists hypersensitivity reactions, serious skin disorders, hepatic adverse reactions and Clostridioides difficile-associated diarrhoea among its warnings. Please read the full label.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
